These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 29615338)

  • 1. Use of the Ion AmpliSeq Cancer Hotspot Panel in clinical molecular pathology laboratories for analysis of solid tumours: With emphasis on validation with relevant single molecular pathology tests and the Oncomine Focus Assay.
    Lee A; Lee SH; Jung CK; Park G; Lee KY; Choi HJ; Min KO; Kim TJ; Lee EJ; Lee YS
    Pathol Res Pract; 2018 May; 214(5):713-719. PubMed ID: 29615338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material.
    de Leng WW; Gadellaa-van Hooijdonk CG; Barendregt-Smouter FA; Koudijs MJ; Nijman I; Hinrichs JW; Cuppen E; van Lieshout S; Loberg RD; de Jonge M; Voest EE; de Weger RA; Steeghs N; Langenberg MH; Sleijfer S; Willems SM; Lolkema MP
    PLoS One; 2016; 11(2):e0149405. PubMed ID: 26919633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of the Oncomine
    Williams HL; Walsh K; Diamond A; Oniscu A; Deans ZC
    Virchows Arch; 2018 Oct; 473(4):489-503. PubMed ID: 30105577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementation of next generation sequencing technology for somatic mutation detection in routine laboratory practice.
    Giardina T; Robinson C; Grieu-Iacopetta F; Millward M; Iacopetta B; Spagnolo D; Amanuel B
    Pathology; 2018 Jun; 50(4):389-401. PubMed ID: 29752127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards a Next-Generation Sequencing Diagnostic Service for Tumour Genotyping: A Comparison of Panels and Platforms.
    Burghel GJ; Hurst CD; Watson CM; Chambers PA; Dickinson H; Roberts P; Knowles MA
    Biomed Res Int; 2015; 2015():478017. PubMed ID: 26351634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Versatile ion S5XL sequencer for targeted next generation sequencing of solid tumors in a clinical laboratory.
    Mehrotra M; Duose DY; Singh RR; Barkoh BA; Manekia J; Harmon MA; Patel KP; Routbort MJ; Medeiros LJ; Wistuba II; Luthra R
    PLoS One; 2017; 12(8):e0181968. PubMed ID: 28767674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing.
    Zhang L; Chen L; Sah S; Latham GJ; Patel R; Song Q; Koeppen H; Tam R; Schleifman E; Mashhedi H; Chalasani S; Fu L; Sumiyoshi T; Raja R; Forrest W; Hampton GM; Lackner MR; Hegde P; Jia S
    Oncologist; 2014 Apr; 19(4):336-43. PubMed ID: 24664487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive evaluation and validation of targeted next-generation sequencing performance in two clinical laboratories.
    Mendez P; Dang J; Kim JW; Lee S; Yoon JH; Kim T; Sailey CJ; Jablons DM; Kim IJ
    Int J Oncol; 2016 Jul; 49(1):235-42. PubMed ID: 27121194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter validation of cancer gene panel-based next-generation sequencing for translational research and molecular diagnostics.
    Hirsch B; Endris V; Lassmann S; Weichert W; Pfarr N; Schirmacher P; Kovaleva V; Werner M; Bonzheim I; Fend F; Sperveslage J; Kaulich K; Zacher A; Reifenberger G; Köhrer K; Stepanow S; Lerke S; Mayr T; Aust DE; Baretton G; Weidner S; Jung A; Kirchner T; Hansmann ML; Burbat L; von der Wall E; Dietel M; Hummel M
    Virchows Arch; 2018 Apr; 472(4):557-565. PubMed ID: 29374318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of different massive parallel sequencing platforms for mutation profiling in formalin-fixed and paraffin-embedded samples].
    Jiang RR; Wang YJ; Teng XD; Xiao L; Bu H; Ye F
    Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):591-596. PubMed ID: 30107663
    [No Abstract]   [Full Text] [Related]  

  • 11. Validation of a next-generation-sequencing cancer panel for use in the clinical laboratory.
    Simen BB; Yin L; Goswami CP; Davis KO; Bajaj R; Gong JZ; Peiper SC; Johnson ES; Wang ZX
    Arch Pathol Lab Med; 2015 Apr; 139(4):508-17. PubMed ID: 25356985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service.
    Hamblin A; Wordsworth S; Fermont JM; Page S; Kaur K; Camps C; Kaisaki P; Gupta A; Talbot D; Middleton M; Henderson S; Cutts A; Vavoulis DV; Housby N; Tomlinson I; Taylor JC; Schuh A
    PLoS Med; 2017 Feb; 14(2):e1002230. PubMed ID: 28196074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors.
    Luthra R; Patel KP; Routbort MJ; Broaddus RR; Yau J; Simien C; Chen W; Hatfield DZ; Medeiros LJ; Singh RR
    J Mol Diagn; 2017 Mar; 19(2):255-264. PubMed ID: 28017569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical validation of the 50 gene AmpliSeq Cancer Panel V2 for use on a next generation sequencing platform using formalin fixed, paraffin embedded and fine needle aspiration tumour specimens.
    Rathi V; Wright G; Constantin D; Chang S; Pham H; Jones K; Palios A; Mclachlan SA; Conron M; McKelvie P; Williams R
    Pathology; 2017 Jan; 49(1):75-82. PubMed ID: 27913044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of cytocentrifugation supernatant fluid and formalin-fixed paraffin-embedded tissue for targeted next-generation sequencing.
    Janaki N; Harbhajanka A; Michael CW; Bomeisl P; Wasman J; Atchley M; Miskiewicz K; Alouani D; Sadri N
    Cancer Cytopathol; 2019 May; 127(5):297-305. PubMed ID: 30933438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours.
    Singh RR; Patel KP; Routbort MJ; Aldape K; Lu X; Manekia J; Abraham R; Reddy NG; Barkoh BA; Veliyathu J; Medeiros LJ; Luthra R
    Br J Cancer; 2014 Nov; 111(10):2014-23. PubMed ID: 25314059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality control material for the detection of somatic mutations in fixed clinical specimens by next-generation sequencing.
    Dumur CI; Almenara JA; Powers CN; Ferreira-Gonzalez A
    Diagn Pathol; 2015 Sep; 10():169. PubMed ID: 26376646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Routine use of the Ion Torrent AmpliSeq™ Cancer Hotspot Panel for identification of clinically actionable somatic mutations.
    Tsongalis GJ; Peterson JD; de Abreu FB; Tunkey CD; Gallagher TL; Strausbaugh LD; Wells WA; Amos CI
    Clin Chem Lab Med; 2014 May; 52(5):707-14. PubMed ID: 24334431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Analyses of Targeted Myeloid Cancer Next-Generation Sequencing Panel in Fresh Blood, Bone Marrow and FFPE Material.
    Hobeck AD; Wendt S; Krohn S; Knuebel G; Bartels S; Schipper E; Junghanss C; Murua Escobar H
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HaloPlex Targeted Resequencing for Mutation Detection in Clinical Formalin-Fixed, Paraffin-Embedded Tumor Samples.
    Moens LN; Falk-Sörqvist E; Ljungström V; Mattsson J; Sundström M; La Fleur L; Mathot L; Micke P; Nilsson M; Botling J
    J Mol Diagn; 2015 Nov; 17(6):729-39. PubMed ID: 26354930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.